MindRank Announces First Patient Dosed in Phase III Trial of AI-Designed Oral GLP-1 Receptor Agonist MDR-001SHANGHAI, China, Feb. 25, 2026 (GLOBE NEWSWIRE) -- MindRank, a clinical-stage artificial intelligence (AI)-empowered drug discovery company, today announced that the first patient has been dosed in the Phase III clinical trial of MDR-001, its AI-designed oral small-molecule GLP-1 receptor agonist (GLP-1RA) for the treatment of obesity and type 2 diabetes in China.
MindRank Initiates Phase III "MOBILE" Trial for MDR-001: an Oral GLP-1RA Small Molecule Engineered with AIHANGZHOU, China, Jan. 06, 2026 (GLOBE NEWSWIRE) -- MindRank, a clinical-stage artificial intelligence (AI)-empowered drug discovery company, today announced the initiation of "MOBILE," a pivotal Phase III clinical trial evaluating its lead candidate, MDR-001. MDR-001 is a proprietary, orally available GLP-1 receptor agonist (GLP-1RA) for chronic weight management, developed using the company's Molecule Pro™ AI platform.
MindRank Announces Positive 12-week Once-Daily (QD) Results for AI-Designed Oral GLP-1 Agonist MDR-001 in Adults with ObesityHANGZHOU, China and LONDON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- MindRank AI Ltd., a clinical-stage artificial intelligence (AI)-empowered drug discovery company, today announced the positive topline results of its oral small-molecule GLP-1 receptor agonist MDR-001 in adults with overweight or obesity. Using an optimized once-daily (QD) regimen, MDR-001 achieved a body weight reduction of 8.9% over 12 weeks, compared to 0.6% in the placebo group (P<0.001), yielding a placebo-adjusted mean weight loss of 8.3%, with a favorable safety and tolerability profile.
MindRank Presented Clinical Update on Oral GLP-1RA MDR-001 at LSX World Congress, Highlighting AI-Powered InnovationHANGZHOU, China and LONDON, Sept. 18, 2025 (GLOBE NEWSWIRE) -- MindRank, a clinical-stage artificial intelligence (AI)-empowered drug discovery company, was invited to present at the 2025 LSX World Congress in Boston. The company delivered a keynote presentation entitled “AI-Designed Oral GLP-1RA: First-in-Class Phase IIb Clinical Readouts and Translational Insights”. This marks the first international presentation of MDR-001’s update clinical results, sparking significant interest and discussion among global industry experts and corporate leaders.
MindRank Announces Positive Phase 2b Results for AI-Designed Oral GLP-1 Receptor Agonist MDR-001 in Adults with Obesity or OverweightHANGZHOU, China and LONDON, June 24, 2025 (GLOBE NEWSWIRE) -- MindRank, a clinical stage artificial intelligence (AI)-empowered drug discovery company, today announced positive topline results from a Phase 2b clinical trial of its proprietary AI-designed oral GLP-1 receptor agonist (GLP-1RA), MDR-001, in adults with obesity or overweight in China.
